KCTD20 (potassium channel tetramerization domain containing 20) is a positive regulator of AKT signaling that plays crucial roles in cell survival, proliferation, and disease pathogenesis. KCTD20 binds to all AKT isoforms and protein phosphatase 2A (PP2A), inhibiting PP2A-mediated dephosphorylation of AKT and thereby maintaining AKT activation 1. This mechanism promotes AKT phosphorylation at Thr308, positioning KCTD20 as a key mediator of cell survival pathways 1. In cancer contexts, KCTD20 functions as an oncogene, promoting tumor cell proliferation and invasion through activation of the FAK/AKT pathway in non-small cell lung cancer, where its overexpression correlates with advanced disease stage and poor patient survival 2. The protein also contributes to glioma progression by promoting cell proliferation and inhibiting apoptosis 3. Conversely, KCTD20 has pathological roles in neurodegenerative diseases, where its suppression ameliorates tau pathology and neurodegeneration by activating lysosomal exocytosis to clear toxic tau species 4. Additionally, KCTD20 contributes to neuronal toxicity in Parkinson's disease models 5 and shows association with cocaine dependence through genome-wide association studies 6. The protein is ubiquitously expressed across nervous and non-nervous tissues, suggesting broad physiological importance 1.